Accelerated atherosclerosis in systemic lupus erythematosus: Role of proinflammatory cytokines and therapeutic approaches

Current Allergy and Asthma Reports

Volumn 12, Issue 1, 2012, Pages 25-32

  Frieri, Marianne ^a  

^a NASSAU UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; Cardiovascular diseases; Lupus nephritis; Proinflammatory cytokines; SLE; Systemic lupus erythematosus; Therapeutic agents; Therapy

Indexed keywords

BELIMUMAB; CD40 LIGAND; CYTOKINE; DOUBLE STRANDED DNA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 9; VASCULOTROPIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CASE REPORT; CLINICAL OBSERVATION; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ACTIVITY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; KIDNEY BIOPSY; LIPID TRANSPORT; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE; MALE; PATHOGENESIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; CD40 LIGAND; CYTOKINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857633905     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-011-0236-1     Document Type: Article

References (28)

1. M McMahon BH Hahn 2007 Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association Curr Opin Immunol 19 6 633 9 18083018 10.1016/j.coi.2007.11.001 1:CAS:528:DC%2BD2sXhsVCksb7F (Pubitemid 350236815)
2. HJ Fu M Yuan LF Ren WY Guo 2011 The clinical research of serum soluble CD40L and high sensitive C-reactive protein in patients with acute coronary syndrome Xi Bao Yu Fen ZiMian Yi XueZaZhi 27 2 180 1 1:CAS:528: DC%2BC3MXmtlSrsbc%3D This was an important study reviewing CD40L and inflammation related to ACS.
3. K Shimizu RN Mitchell P Libby 2006 Inflammation and cellular immune responses in abdominal aortic aneurysms Arterioscler Thromb Vasc Biol 26 5 987 94 16497993 10.1161/01.ATV.0000214999.12921.4f 1:CAS:528:DC%2BD28XjsVers7g%3D (Pubitemid 43732102)
4. Steele R, Frieri M. Heat shock protein and sCD40 L stimulation of human keratinocytes. A model for cytokine profiling for cutaneous lupus. J Allergy Clin Immunol. 2008;121:P871.
5. JC Yedowitz M Frieri 2009 Cytokine and growth factor production from chlamydia pneumoniae HSP 60 stimulated human aortic endothelial cells in the presence of simvastatin Ann Allergy Asthma Immunol 102 P113
6. R Seghal A Jabber A Anand A Capetandes M Frieri 2009 Monitoring CD 40 ligand in patients with SLE J Allergy Clin Immunol 123 S16 10.1016/j.jaci.2008. 12.075
7. •• Frieri M. TLR and VEGF in human kidneys from lupus nephritis patients. J Nephrology. 2011, In review. This was a novel basic science study on the role of TLRs and VEGF in human kidneys from LN patients.
8. AC Shirali DR Goldstein 2008 Tracking the toll of kidney disease J Am Soc Nephrol 19 8 1444 50 18579638 10.1681/ASN.2008010123 1:CAS:528: DC%2BD1cXhtVWltrzK
9. A Tedgui Z Mallat 2006 Cytokines in atherosclerosis: pathogenic and regulatory pathways Physiol Rev 86 515 81 16601268 10.1152/physrev.00024.2005 1:CAS:528:DC%2BD28Xktlylu7g%3D
10. AH Sprague RA Khalil 2009 Inflammatory cytokines in vascular dysfunction and vascular disease Biochem Pharmacol 78 6 539 52 19413999 10.1016/j.bcp.2009. 04.029 1:CAS:528:DC%2BD1MXpt1Kls7w%3D
11. U Schönbeck P Libby 2001 CD40 signaling and plaque instability Circ Res 89 12 1092 103 11739273 10.1161/hh2401.101272 (Pubitemid 34627866)
12. EF Borba E Bonfa 2001 Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy J Rheumatol 28 780 5 11327250 1:CAS:528:DC%2BD3MXivVGrtLk%3D (Pubitemid 32246946)
13. C Yildirim-Toruner B Diamond 2011 Current and novel therapeutics in the treatment of systemic lupus erythematosus J Allergy Clin Immunol 127 303 12 21281862 10.1016/j.jaci.2010.12.1087 1:CAS:528:DC%2BC3MXhtlSqtbo%3D This is a very important, up-to-date, detailed article on novel therapies for SLE.
14. SE Dunn S Youssef MJ Goldstein T Prod'homme MS Weber SS Zamvil, et al. 2006 Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin J Exp Med 203 401 12 16476765 10.1084/jem.20051129 1:CAS:528:DC%2BD28XhslClt70%3D (Pubitemid 43290849)
15. C Lopez-Pedrera 2009 Global effects of the HMG-CoA reductase inhibitor fluvastatin on the procoagulant and proinflammatory features of monocytes from APS patients Ann Rheum Dis 68 suppl 3 245
16. GA Ferreira TP Navarro RW Telles LE Andrade EI Sato 2007 Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial Rheumatology (Oxford) 46 1560 5 10.1093/rheumatology/kem186 1:CAS:528:DC%2BD2sXhsVWgsLrM (Pubitemid 47500570)
17. PJ Kotyla B Sliwinska-Kotyla EJ Kucharz 2006 Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMGCoA reductase inhibitor simvastatin J Rheumatol 33 2361 3 17086617 (Pubitemid 44749805)
18. S Bianchi R Bigazzi A Caiazza VM Campese 2003 A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Am J Kidney Dis 41 565 70 12612979 10.1053/ajkd.2003.50140 1:CAS:528:DC%2BD3sXisVOjurk%3D (Pubitemid 36278373)
19. BT Kurien RH Scofield 2008 Autoimmunity and oxidatively modified autoantigens Autoimmun Rev 7 7 567 73 18625446 10.1016/j.autrev.2008.04.019 1:CAS:528:DC%2BD1cXhtVCntrjP
20. K Fischer M Brzosko 2009 Diagnosis of early atherosclerotic lesions, and selected atherosclerotic risk factors, in patients with systemic lupus erythematosus Pol Arch Med Wewn 119 11 736 42 19920799
21. A Torres AD Askari CJ Malemud 2009 Cardiovascular disease complications in systemic lupus erythematosus Biomarkers Med 3 3 239 52 10.2217/bmm.09.14 1:CAS:528:DC%2BD1MXms12itr4%3D This is a useful article on various cardiovascular issues related to SLE.
22. AB Reiss 2009 Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus Curr Rheumatol Rep 11 4 255 60 19691928 10.1007/s11926-009-0036-y 1:CAS:528:DC%2BC3cXhtFeku7vK This is an extensive review on the role of inflammation and cholesterol related to SLE.
23. Reiss AB. Presented at the American Federation of Medical Research Workshop-, April 27, 2011.
24. Frieri M. Cardiovascular risk in autoimmune rheumatic disorder. Presented at the American Federation of Medical Research Workshop, April 27, 2011.
25. AB Reiss, et al. 2009 Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis Exp Biol Med 234 3 354 60 10.3181/0806-BC-194 1:CAS:528:DC%2BD1MXivFehtLo%3D
26. Reiss AB, Patel CA, Rahman M, Chan ES, Hasneen K, Montesinos C, Trahman JD, Cronstein BN. Interferon-gamma impedes reverse cholesterol transport and promotes foam cell transformation in THP-1 human monocytes/macrophages. Med Sci Monit. 2004;1-:BR420-BR425. (Pubitemid 39546030)
27. TC Bingham EA Fisher S Parathath AB Reiss ES Chan BN Cronstein 2010 A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux J Leukoc Biol 87 4 683 90 20089670 10.1189/jlb.0709513 1:CAS:528:DC%2BC3cXmvVChsbc%3D
28. •• Lopez-Pedrera C, Angeles Aguirre M, Barbarroja N. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol. Volume. 2010, Article ID 607084, 13. This is an excellent article on the role of cytokines and treatments related to accelerated atherosclerosis in SLE.